Coherus Oncology, Inc.

CHRS Healthcare Biotechnology

In the quarter to June 2026, revenue grew 39.5%, EPS fell 105.1%, free cash flow fell 33.2% and total debt rose 1.03%, each against the same quarter a year earlier.

1.00 0.07 −6.54%
Market cap
$165.3M
P/E
0.0×
Fwd P/E
−1.4×
Dividend yield
—
F-score
6/9
Altman Z
−8.83
Beneish M
−3.44
Dividend safety
n/a

A Balance Sheet is a financial statement that provides a snapshot of a company's assets, liabilities, and shareholders' equity at a specific point in time. It follows the formula: Assets = Liabilities + Shareholders' Equity. Key components include current and non-current assets, current and long-term liabilities, and equity. The Balance Sheet helps businesses and investors evaluate financial stability, liquidity, and capital structure. It's essential for assessing the company's ability to meet its obligations and fund future operations.

Dec '16 Dec '17 Dec '18 Dec '19 Dec '20 Dec '21 Dec '22 Dec '23 Dec '24 Dec '25
Cash and Short Term Investments
125.01 126.97 72.41 177.67 541.16 417.20 191.68 117.75 125.99 172.13
Receivables
1.86 — — 141.99 157.05 123.02 109.96 260.52 122.33 18.42
Inventory
— — 1.66 9.81 44.23 37.64 38.79 62.61 4.21 3.17
Other current assets
34.62 3.54 2.46 4.96 5.61 10.80 22.92 11.10 10.22 6.23
Total current assets
161.49 145.48 84.43 343.01 767.48 602.32 381.23 475.63 341.58 206.71
Property, Plant, Equpment (Net)
10.77 12.77 6.66 5.84 10.11 7.81 8.75 5.12 2.58 1.35
Goodwill and Intangible Assets (Total)
3.56 3.56 3.56 3.56 3.56 3.56 5.93 71.67 53.65 46.24
Long-term assets (Other)
2.66 0.80 0.80 0.60 12.54 10.03 8.67 9.69 6.49 4.05
Total non-current assets
17.00 17.13 15.03 65.92 74.17 77.01 99.61 153.97 106.95 51.64
Total Assets
178.49 162.61 99.47 408.93 841.65 679.33 480.85 629.60 448.53 258.34
Accounts Payable
20.58 15.71 15.29 25.99 15.20 16.16 11.53 35.22 28.46 9.92
Accrued Expenses
28.02 9.05 17.55 86.79 130.45 149.17 127.17 296.55 254.53 130.47
Current Revenue (Deferred)
0.89 — — — — — — — — —
Other current liabilities
6.88 3.63 0.42 2.20 — — — — — —
Total current liabilities
56.38 28.40 33.26 114.97 145.65 165.33 138.69 331.77 282.98 140.39
Long Term Debt (Total)
100.26 101.61 103.09 178.39 404.02 408.28 471.06 473.37 264.93 37.05
Non-current Revenue (Deferred)
0.67 — — — — — — — — —
Non-current Liabilities (Other)
1.83 2.07 1.71 0.10 1.05 0.75 3.47 12.56 29.33 18.44
Total non-current liabilities
102.76 103.68 104.80 188.74 415.02 416.28 479.57 491.26 297.54 56.94
Total liabilities
159.13 132.08 138.06 303.71 560.68 581.61 618.27 823.03 580.52 197.33
Additional Paid In Capital
558.47 808.06 946.52 1,000.76 1,043.99 1,147.84 1,204.43 1,386.31 1,419.27 1,444.17
Common Stock (Net)
0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01 0.01
Retained Earnings
(537.32) (775.49) (984.83) (895.00) (762.75) (1,049.85) (1,341.61) (1,579.50) (1,550.99) (1,382.97)
Common Equity (Total)
19.35 30.54 (38.59) 105.21 280.97 97.73 (137.42) (193.42) (131.99) 61.01
Shareholders Equity (Total)
19.35 30.54 (38.59) 105.21 280.97 97.73 (137.42) (193.42) (131.99) 61.01
Shareholders Equity and Liabilities (Total)
178.49 162.61 99.47 408.93 841.65 679.33 480.85 629.60 448.53 258.34
Shares (Common)
45.81 59.84 68.30 70.37 72.51 76.93 78.85 112.22 115.62 121.16
Shareholders Equity (Tangible)
15.79 26.97 (42.15) 101.65 277.41 94.16 (143.35) (265.10) (185.64) 14.78
Net Debt
(24.75) (25.36) 30.69 0.72 (137.13) (8.91) 279.38 355.62 138.94 (135.07)
Total Debt
100.26 101.61 103.09 178.39 404.02 408.28 471.06 473.37 264.93 37.05

Fold the line items

In millions of $ except per-share values · columns are period end dates